Skip to main content

Table 3 Major molecular alterations in small bowel adenocarcinoma described by others in comparison to our study

From: Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma

References

No. of patients

TP53 (%)

KRAS (%)

ERBB2 (%)

MSi (%)

BRCA (%)

Hänninen et al. (2018) [1]

106

48

47

14

14.1

5

Schrock et al. (2017) [10]

317

51

53.6

8.2

7.6

n.a

Laforest et al. (2014) [26]

83

41

43

12

21

n.a

Overman et al. (2012) [7]

54

–

–

–

–

n.a

Planck et al. (2003) [31]

89

–

–

–

–

n.a

Quaas et al. (2018) [24]

11

55

45

9

20

36

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us